Whipple disease

Current Opinion in Gastroenterology

Volumn 24, Issue 2, 2008, Pages 141-148

  Marth, Thomas ^a   Schneider, Thomas ^b  

^a Chirurgische Klinik   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Macrophage; PCR; T cell; Therapy; Whipple disease

Indexed keywords

CARBAPENEM; CEFIXIME; CEFTRIAXONE; CEPHALOSPORIN; CHLORAMPHENICOL; CORTICOSTEROID; COTRIMOXAZOLE; DOXYCYCLINE; HYDROXYCHLOROQUINE; PENICILLIN G; STREPTOMYCIN; SULFAMETHOXAZOLE; TETRACYCLINE; TRIMETHOPRIM;

ALLERGIC REACTION; ANTIBIOTIC THERAPY; CLINICAL FEATURE; DEMOGRAPHY; DISEASE COURSE; DRUG EFFICACY; DRUG POTENTIATION; ELECTRON MICROSCOPY; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE LIPODYSTROPHY; MONOTHERAPY; NONHUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; REVIEW; RNA SEQUENCE; T LYMPHOCYTE; TROPHERYMA WHIPPELII;

HUMANS; TROPHERYMA; WHIPPLE DISEASE;

EID: 40049090377     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3282f3f4f1     Document Type: Review

References (50)

1. Cohen AS, Schimmel EM, Holt PR, Isselbacher KJ. Ultrastructural abnormalities in Whipple's disease. Proc Soc Exp Biol Med 1960; 105:411-414.
2. Yardley JH, Hendrix TR. Combined electron and light microscopy in Whipple's disease: demonstration of 'bacillary bodies' in the intestine. Bull Johns Hopkins Hosp 1961; 109:80-98. Important evidence on the bacterial nature of Whipple disease.
3. Wilson KH, Blitchington R, Frothingham R, Wilson JA. Phylogeny of the Whipple's-disease-associated bacterium. Lancet 1991; 338:474-475. First pylogenetic characterization of the agent of Whipple disease.
4. Relman DA, Schmidt TM, MacDermott RP, Falkow S. Identification of the uncultured bacillus of Whipple's disease. N Engl J Med 1992; 327:293-301. Detailed phylogenetic description of T. whippelii by PCR.
5. Raoult D, Birg ML, La Scola B, et al. Cultivation of the bacillus of Whipple's disease. N Engl J Med 2000; 342:620-625. First cultivation of the bacillus of Whipple disease on permanent cell lines, laying the basis for subsequent experimental approaches with the use of the agent T. whipplei.
6. La Scola B, Fenollar F, Fournier PE, et al. Description of Tropheryma whipplei gen. nov., sp. nov., the Whipple's disease bacillus. Int J Syst Evol Microbiol 2001; 51:1471-1479. Following cultivation, the characterization and deposition of the bacterium led to the official name.
7. Marth T, Kleen N, Stallmach A, et al. Dysregulated peripheral and mucosal Th1/Th2 response in Whipple's disease. Gastroenterology 2002; 123:1468-1477.
8. Feurle GE, Marth T. An evaluation of antimicrobial treatment for Whipple's disease: tetracycline versus trimethoprim-sulfamethoxazole. Dig Dis Sci 1994; 39:1642-1648.
9. Fleming JL, Wiesner RH, Shorter RG. Whipple's disease: clinical, biochemical, and histopathologic features and assessment of treatment in 29 patients. Mayo Clin Proc 1988; 63:539-551. A very good characterization of clinical and laboratory findings in Whipple's disease.
10. Marth T, Raoult D. Whipple's disease. Lancet 2003; 361:239-246.
11. Schoedon G, Goldenberger D, Forrer R, et al. Deactivation of macrophages with interleukin-4 is the key to the isolation of Tropheryma whippelii. J Infect Dis 1997; 176:672-677.
12. Renesto P, Crapoulet N, Ogata H, et al. Genome-based design of a cell-free culture medium for Tropheryma whipplei. Lancet 2003; 362:447-449.
13. Raoult D, Ogata H, Audic S, et al. Tropheryma whipplei Twist: a human pathogenic actinobacteria with a reduced genome. Genome Res 2003; 13:1800-1809. Genomic analysis of the Whipple disease bacterium with insights into its characteristics, such as reduced genome ('parasitic bacterium') and lack of amino acid pathways ('host dependance').
14. Bentley SD, Maiwald M, Murphy LD, et al. Sequencing and analysis of the genome of the Whipple's disease bacterium Tropheryma whipplei. Lancet 2003; 361:637-644. Genomic analysis of the Whipple disease bacterium with insights into its characteristics, such as reduced genome ('parasitic bacterium') and lack of amino acid pathways ('host dependance').
15. Genot S, Stein A, Lepidi H, et al. Murine model of infection by Tropheryma whipplei. Infect Immunity 2006; 74:4915-4917.
16. Geissdorfer W, Wittmann I, Rollinghoff M, et al. Detection of a new 16S-23S rRNA spacer sequence variant (type 7) of Tropheryma whippelii in a patient with prosthetic aortic valve endocarditis. Eur J Clin Microbiol Infect Dis 2001; 20:762-763.
17. Maiwald M, Ditton H, von Herbay A, et al. Reassessment of the phylogenetic position of the bacterium associated with Whipple's disease and determination of the 16S-23S ribosomal intergenic spacer sequence. Int J Syst Bacteriol 1996; 46:1078-1082.
18. Lepidi H, Fenollar F, Dumler JS, et al. Cardiac valves in patients with Whipple endocarditis: microbiological, molecular, quantitative histologic, and immunohistochemical studies of 5 patients. J Infect Dis 2004; 190: 935-945. Description of histological changes in Whipple endocarditis.
19. Ehrbar HU, Bauerfeind P, Dutly F, et al. PCR-positive tests for Tropheryma whippelii in patients without Whipple's disease. Lancet 1999; 353:2214.
20. Street S, Donoghue HD, Neild GH. Tropheryma whippelii DNA in saliva of healthy people. Lancet 1999; 354:1178-1179.
21. Zinkernagel AS, Gmur R, Fenner L, et al. Marginal and subgingival plaque: a natural habitat of Tropheryma whipplei? Infection 2003; 31:86-91.
22. Rolain JM, Fenollar F, Raoult D. False positive PCR detection of Tropheryma whipplei in the saliva of healthy people. BMC Microbiol 2007; 7:48.
23. Maiwald M, Schuhmacher F, Ditton HJ, von Herbay A. Environmental occurrence of the Whipple's disease bacterium (Tropheryma whippelii). Appl Environ Microbiol 1998; 64:760-762. First molecular data on the ubiquitous presence of the bacterium.
24. Maiwald M, von Herbay A, Persing DH, et al. Tropheryma whippelii DNA is rare in the intestinal mucosa of patients without other evidence of Whipple disease. Ann Intern Med 2001; 134:115-119.
25. Schoniger-Hekele M, Petermann D, Weber B, Muller C. Tropheryma whipplei in the environment: survey of sewage plant influxes and sewage plant workers. Appl Environ Microbiol 2007; 73:2033-2035.
26. Marth T, Roux M, von Herbay A, et al. Persistent reduction of complement receptor 3 alpha-chain expressing mononuclear blood cells and transient inhibitory serum factors in Whipple's disease. Clin Immunol Immunopathol 1994; 72:217-226.
27. Marth T, Neurath M, Cuccherini BA, Strober W. Defects of monocyte interleukin 12 production and humoral immunity in Whipple's disease. Gastroenterology 1997; 113:442-448.
28. Moos V, Kunkel D, Marth T, et al. Reduced peripheral and mucosal Tropheryma whipplei-specific Th1 response in patients with Whipple's disease. J Immunol 2006; 177:2015-2022. With the use of T. whipplei antigen, Whipple disease patients showed a specific immune defect compared with various control groups.
29. Desnues B, Raoult D, Mege JL. IL-16 is critical for Tropheryma whipplei replication in Whipple's disease. J Immunol 2005; 175:4575-4582. The work points out the differential role of macrophages and monocytes as host cells for the bacterium, and shows the influence of IL-16 and thioredoxin for the growth of T. whipplei.
30. Desnues B, Lepidi H, Raoult D, Mege JL. Whipple disease: intestinal infiltrating cells exhibit a transcriptional pattern of M2/alternatively activated macrophages. J Infect Dis 2005; 192:1642-1646.
31. Maizel H, Ruffin JM, Dobbins WO 3rd. Whipple's disease: a review of 19 patients from one hospital and a review of the literature since 1950. Medicine (Baltimore) 1970; 49:175-205. One of the earlier case series and an insightful review.
32. Durand DV, Lecomte C, Cathebras P, et al. Whipple disease: clinical review of 52 cases. The SNFMI Research Group on Whipple Disease. Societe Nationale Francaise de Medecine Interne. Medicine (Baltimore) 1997; 76:170-184.
33. Keinath RD, Merrell DE, Vlietstra R, Dobbins WO 3rd. Antibiotic treatment and relapse in Whipple's disease: long-term follow-up of 88 patients. Gastroenterology 1985; 88:1867-1873. A careful study about the outcome in treatment of Whipple's disease.
34. Simpson DA, Wishnow R, Gargulinski RB, Pawlak AM. Oculofacial-skeletal myorhythmia in central nervous system Whipple's disease: additional case and review of the literature. Mov Disord 1995; 10:195-200.
35. Gerard A, Sarrot-Reynauld F, Liozon E, et al. Neurologic presentation of Whipple disease: report of 12 cases and review of the literature. Medicine (Baltimore) 2002; 81:443-457. A very good overview of the neurological manifestations in Whipple's disease.
36. Mendel E, Khoo LT, Go JL, et al. Intracerebral Whipple's disease diagnosed by stereotactic biopsy: a case report and review of the literature. Neurosurgery 1999; 44:203-209.
37. von Herbay A, Ditton HJ, Schumacher F, Maiwald M. Whipple's disease: staging and monitoring by cytology and polymerase chain reaction analysis of cerebrospinal fluid. Gastroenterology 1997; 113:434-441. Describes the value of PCR in the cerebrospinal fluid of patients with Whipple's disease.
38. Feurle GE, Maiwald M, Moos V, et al. Randomized controlled trial of antimicrobial treatment in Whipple's disease (SIMW) [abstract]. Gastroenterology 2007; 132 (Suppl S1):639.
39. Panegyres PK, Edis R, Beaman M, Fallon M. Primary Whipple's disease of the brain: characterization of the clinical syndrome and molecular diagnosis. QJM 2006; 99:609-623.
40. Avila MP, Jalkh AE, Feldman E, et al. Manifestations of Whipple's disease in the posterior segment of the eye. Arch Ophthalmol 1984; 102:384-390.
41. O'Duffy JD, Griffing WL, Li CY, et al. Whipple's arthritis: direct detection of Tropheryma whippelii in synovial fluid and tissue. Arthritis Rheum 1999; 42:812-817. Describes the value of PCR from synovial fluid in patients with primary arthralgic manifestations in Whipple's disease.
42. Puechal X. Whipple disease and arthritis. Curr Opin Rheumatol 2001; 13:74-79.
43. Marin M, Munoz P, Sanchez M, et al. Tropheryma whipplei infective endocarditis as the only manifestation of Whipple's disease. J Clin Microbiol 2007; 45:2078-2081.
44. Houpikian P, Raoult D. Blood culture-negative endocarditis in a reference center: etiologic diagnosis of 348 cases. Medicine 2005; 84:162-173. An analysis of culture-negative endocarditis in France.
45. Baisden BL, Lepidi H, Raoult D, et al. Diagnosis of Whipple disease by immunohistochemical analysis: a sensitive and specific method for the detection of Tropheryma whipplei (the Whipple bacillus) in paraffin-embedded tissue. Am J Clin Pathol 2002; 118:742-748.
46. Cooper GS, Blades EW, Remler BF, et al. Central nervous system Whipple's disease: relapse during therapy with trimethoprim-sulfamethoxazole and remission with cefixime. Gastroenterology 1994; 106:782-786.
47. Boulos A, Rolain JM, Raoult D. Antibiotic susceptibility of Tropheryma whipplei in MRC5 cells. Antimicrob Agents Chemother 2004; 48:747-752.
48. Van La M, Barbry P, Raoult D, Renesto P. Molecular basis of Tropheryma whipplei doxycycline susceptibility examined by transcriptional profiling. J Antimicrob Chemother 2007; 59:370-377.
49. Ghigo E, Capo C, Aurouze M, et al. Survival of Tropheryma whipplei, the agent of Whipple's disease, requires phagosome acidification. Infect Immun 2002; 70:1501-1506.
50. Schneider T, Stallmach A, von Herbay A, et al. Treatment of refractory Whipple disease with interferon-gamma. Ann Intern Med 1998; 129:875-877.